<DOC>
	<DOCNO>NCT00423215</DOCNO>
	<brief_summary>The objective protocol confirm efficacy safety profile Lantus every day medical practice , type 2 diabetic patient , treat insulin reach target A1c = 7 % .</brief_summary>
	<brief_title>LAPAS Study : Insulin Glargine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 2 diabetes mellitus , Having treat insulin , reach target A1c=7 % . Ability willingness perform Self Monitoring Blood Glucose measurement Will follow prescribe information ( Summary Product Characteristics ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>